---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-081941"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:02:28.685654+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper appoints Thomas G. Wiggans as Chairperson; William Lis to retire in Dec 2023

## Summary
- Thomas G. Wiggans joins Board as Class II director and Chairperson effective Nov 1, 2023.
- Wiggans, 71, is former CEO/founder of Dermira (acquired by Lilly), ex-CEO of Pardes Biosciences.
- Wiggans receives option to purchase 110,000 shares, vesting over 4 years; larger than standard director grant.
- William Lis steps down as Chairperson immediately, will resign from Board on Dec 14, 2023 (no disagreement).
- Company focuses on briquilimab for mast cell diseases and LR-MDS; initial CSU study launching.

## SEC filing metadata
- accession: 0001213900-23-081941
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/0001213900-23-081941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/ea187564-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-081941
- JSON: https://secwatch.observer/filing/0001213900-23-081941.json
- Plain text: https://secwatch.observer/filing/0001213900-23-081941.txt

## Key facts
- Executive change
  Thomas G. Wiggans was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: Chairperson of the Board
  source text: Effective November 1, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Thomas G. Wiggans as a Class II director of the Company. Mr. Wiggans was also appointed to serve as Chairperson of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023081941/0001213900-23-081941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.